Wall Street brokerages expect Fresenius Medical Care Corporation (NYSE:FMS) to announce earnings per share (EPS) of $0.58 for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Fresenius Medical Care Corporation’s earnings, with estimates ranging from $0.54 to $0.61. Fresenius Medical Care Corporation reported earnings of $0.54 per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 7.4%. The business is expected to report its next earnings results on Thursday, October 26th.

According to Zacks, analysts expect that Fresenius Medical Care Corporation will report full year earnings of $2.32 per share for the current fiscal year, with EPS estimates ranging from $2.11 to $2.47. For the next financial year, analysts forecast that the firm will post earnings of $2.55 per share, with EPS estimates ranging from $2.24 to $2.72. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that cover Fresenius Medical Care Corporation.

Fresenius Medical Care Corporation (NYSE:FMS) last released its quarterly earnings data on Tuesday, August 1st. The company reported $0.48 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.53 by $0.05. Fresenius Medical Care Corporation had a net margin of 7.06% and a return on equity of 11.57%. The business had revenue of $4.47 billion for the quarter, compared to the consensus estimate of $5.20 billion. During the same quarter last year, the business earned $0.96 EPS. Fresenius Medical Care Corporation’s revenue for the quarter was up 11.1% compared to the same quarter last year.

Several brokerages have issued reports on FMS. Nord/LB reaffirmed a “buy” rating on shares of Fresenius Medical Care Corporation in a research note on Wednesday, June 28th. Royal Bank Of Canada reaffirmed a “hold” rating and set a $44.00 target price on shares of Fresenius Medical Care Corporation in a research note on Wednesday, July 5th. UBS AG reaffirmed a “sell” rating on shares of Fresenius Medical Care Corporation in a research note on Tuesday, July 4th. Zacks Investment Research raised shares of Fresenius Medical Care Corporation from a “hold” rating to a “buy” rating and set a $54.00 target price on the stock in a research note on Tuesday, July 11th. Finally, BidaskClub cut shares of Fresenius Medical Care Corporation from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 24th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and eight have assigned a buy rating to the stock. Fresenius Medical Care Corporation has an average rating of “Buy” and a consensus price target of $48.67.

Fresenius Medical Care Corporation (FMS) opened at 45.85 on Friday. The firm’s 50-day moving average is $47.66 and its 200 day moving average is $44.76. The company has a market cap of $28.14 billion, a price-to-earnings ratio of 20.02 and a beta of 0.47. Fresenius Medical Care Corporation has a 52-week low of $38.05 and a 52-week high of $50.22.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. UBS Asset Management Americas Inc. boosted its position in Fresenius Medical Care Corporation by 3.6% in the second quarter. UBS Asset Management Americas Inc. now owns 2,357 shares of the company’s stock worth $114,000 after buying an additional 81 shares during the last quarter. Pacer Advisors Inc. bought a new position in Fresenius Medical Care Corporation during the second quarter worth approximately $179,000. Quadrant Capital Group LLC boosted its position in Fresenius Medical Care Corporation by 12.7% in the first quarter. Quadrant Capital Group LLC now owns 3,736 shares of the company’s stock worth $149,000 after buying an additional 420 shares during the last quarter. FFT Wealth Management LLC bought a new position in Fresenius Medical Care Corporation during the second quarter worth approximately $201,000. Finally, HPM Partners LLC bought a new position in Fresenius Medical Care Corporation during the second quarter worth approximately $221,000. 2.84% of the stock is currently owned by institutional investors.

WARNING: This news story was published by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another site, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.watchlistnews.com/0-58-earnings-per-share-expected-for-fresenius-medical-care-corporation-fms-this-quarter/1477167.html.

Fresenius Medical Care Corporation Company Profile

Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.

Get a free copy of the Zacks research report on Fresenius Medical Care Corporation (FMS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Fresenius Medical Care Corporation (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.